JosÃ© Luis Molinuevo

List of Publications by Year
in descending order

276 papers	28,691 citations	13099 68 h-index	6131 159 g-index
289 all docs	289 docs citations	289 times ranked	23884 citing authors

#	Article	IF	Citations
1	NIAâ€AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 535-562.	0.8	5,861
2	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	10.2	2,657
3	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 844-852.	0.8	1,863
4	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
5	Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurology, The, 2006, 5, 572-577.	10.2	901
6	The characterisation of subjective cognitive decline. Lancet Neurology, The, 2020, 19, 271-278.	10.2	627
7	Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurology, The, 2013, 12, 443-453.	10.2	602
8	Alzheimerâ€™s disease prevention: from risk factors to early intervention. Alzheimer's Research and Therapy, 2017, 9, 71.	6.2	424
9	Dementia care during COVID-19. Lancet, The, 2020, 395, 1190-1191.	13.7	412
10	Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. PLoS ONE, 2014, 9, e89741.	2.5	407
11	Current state of Alzheimerâ€™s fluid biomarkers. Acta Neuropathologica, 2018, 136, 821-853.	7.7	370
12	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.8	354
13	Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurology, The, 2010, 9, 1070-1077.	10.2	349
14	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.8	344
15	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease, 2015, 48, S63-S86.	2.6	317
16	Brain structure and function related to cognitive reserve variables in normal aging, mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2009, 30, 1114-1124.	3.1	315
17	Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurology, The, 2011, 10, 797-805.	10.2	293
18	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's and Dementia, 2012, 8, 65-73.	0.8	271

#	Article	IF	Citations
19	Multiple DTI index analysis in normal aging, amnestic MCI and AD. Relationship with neuropsychological performance. Neurobiology of Aging, 2012, 33, 61-74.	3.1	241
20	Subjective cognitive decline and rates of incident Alzheimer's disease and nonâ€“Alzheimer's disease dementia. Alzheimer's and Dementia, 2019, 15, 465-476.	0.8	232
21	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	2.6	215
22	Long-term exposure to residential green and blue spaces and anxiety and depression in adults: A cross-sectional study. Environmental Research, 2018, 162, 231-239.	7.5	208
23	Spanish Multicenter Normative Studies (NEURONORMA Project): Methods and Sample Characteristics. Archives of Clinical Neuropsychology, 2009, 24, 307-319.	0.5	206
24	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. JAMA Neurology, 2021, 78, 1471.	9.0	204
25	Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimerâ€™s continuum when only subtle changes in AÎ² pathology are detected. EMBO Molecular Medicine, 2020, 12, e12921.	6.9	202
26	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for Verbal Fluency Tests. Archives of Clinical Neuropsychology, 2009, 24, 395-411.	0.5	201
27	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	2.4	197
28	Cerebrospinal Fluid AÎ²42/40 Corresponds Better than AÎ²42 to Amyloid PET in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 813-822.	2.6	191
29	Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. Annals of Neurology, 2013, 74, 655-668.	5.3	171
30	Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. Lancet Psychiatry,the, 2016, 3, 179-186.	7.4	171
31	The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimerâ€™s disease risk. Science Translational Medicine, 2019, 11, .	12.4	170
32	Repetitive Transcranial Magnetic Stimulation Effects on Brain Function and Cognition among Elders with Memory Dysfunction. A Randomized Sham-Controlled Study. Cerebral Cortex, 2006, 16, 1487-1493.	2.9	169
33	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's and Dementia, 2014, 10, 808-817.	0.8	163
34	Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1505-1521.	0.8	163
35	Effect of long-term exposure to air pollution on anxiety and depression in adults: A cross-sectional study. International Journal of Hygiene and Environmental Health, 2017, 220, 1074-1080.	4.3	161
36	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for Verbal Span, Visuospatial Span, Letter and Number Sequencing, Trail Making Test, and Symbol Digit Modalities Test. Archives of Clinical Neuropsychology, 2009, 24, 321-341.	0.5	149

#	Article	IF	Citations
37	Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. Movement Disorders, 2002, 17, 372-377.	3.9	148
38	Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimerâ€™s Disease and Related Dementias and Strategic Implications for Stakeholders. Journal of Alzheimer's Disease, 2019, 70, 323-341.	2.6	146
39	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Reviews Neurology, 2015, 11, 41-55.	10.1	144
40	Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Annals of Neurology, 1998, 44, 976-980.	5.3	140
41	Increased Cortical Thickness and Caudate Volume Precede Atrophy in PSEN1 Mutation Carriers. Journal of Alzheimer's Disease, 2010, 22, 909-922.	2.6	136
42	Cognitive reserve modulates task-induced activations and deactivations in healthy elders, amnestic mild cognitive impairment and mild Alzheimer's disease. Cortex, 2010, 46, 451-461.	2.4	136
43	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for the Rey-Osterrieth Complex Figure (Copy and Memory), and Free and Cued Selective Reminding Test. Archives of Clinical Neuropsychology, 2009, 24, 371-393.	0.5	133
44	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
45	Identification of blood serum microâ€RNAs associated with idiopathic and LRRK2 Parkinson's disease. Journal of Neuroscience Research, 2014, 92, 1071-1077.	2.9	122
46	Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease. JAMA - Journal of the American Medical Association, 2018, 319, 130.	7.4	121
47	Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, 1358-1371.	0.8	120
48	Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimerâ€™s Disease: Potential and Limitations. Molecular Neurobiology, 2017, 54, 5550-5562.	4.0	119
49	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.8	113
50	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.8	108
51	Cerebrospinal Fluid Level of YKL-40 Protein in Preclinical and Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 901-908.	2.6	102
52	Effects of APOEâ€Îµ4 allele load on brain morphology in a cohort of middleâ€aged healthy individuals with enriched genetic risk for Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 902-912.	0.8	98
53	Electroencephalographic slowing heralds mild cognitive impairment in idiopathic REM sleep behavior disorder. Sleep Medicine, 2010, 11, 534-539.	1.6	97
54	The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 82-92.	3.7	97

#	Article	IF	Citations
55	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
56	Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy. Journal of Hepatology, 2011, 55, 564-573.	3.7	96
57	Pathophysiological subtypes of Alzheimerâ€™s disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	7.6	89
58	A preliminary study of the whole-genome expression profile of sporadic and monogenic early-onset Alzheimer's disease. Neurobiology of Aging, 2013, 34, 1772-1778.	3.1	87
59	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. Alzheimer's and Dementia, 2018, 14, 1313-1333.	0.8	87
60	Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1259-1272.	0.8	86
61	Significant Changes in the Tau A0 and A3 Alleles in Progressive Supranuclear Palsy and Improved Genotyping by Silver Detection. Archives of Neurology, 1998, 55, 1122.	4.5	85
62	Correlates of cerebrospinal fluid levels of oligomeric- and total-Î±-synuclein in premotor, motor and dementia stages of Parkinsonâ€™s disease. Journal of Neurology, 2015, 262, 294-306.	3.6	85
63	Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimer's Research and Therapy, 2019, 11, 27.	6.2	82
64	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's and Dementia, 2019, 15, 742-753.	0.8	82
65	Interactions of cognitive reserve with regional brain anatomy and brain function during a working memory task in healthy elders. Biological Psychology, 2009, 80, 256-259.	2.2	81
66	Prepulse modulation of the startle reaction and the blink reflex in normal human subjects. Experimental Brain Research, 1999, 129, 49-56.	1.5	79
67	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for the Stroop Color-Word Interference Test and the Tower of London-Drexel. Archives of Clinical Neuropsychology, 2009, 24, 413-429.	0.5	75
68	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for Boston Naming Test and Token Test. Archives of Clinical Neuropsychology, 2009, 24, 343-354.	0.5	74
69	Fiveâ€year followâ€up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder. Movement Disorders, 2014, 29, 1774-1780.	3.9	74
70	A whole-brain computational modeling approach to explain the alterations in resting-state functional connectivity during progression of Alzheimer's disease. NeuroImage: Clinical, 2017, 16, 343-354.	2.7	73
71	Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort. Alzheimer's Research and Therapy, 2018, 10, 123.	6.2	73
72	White matter changes in preclinical Alzheimer's disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid Î² protein 42 levels. Neurobiology of Aging, 2014, 35, 2671-2680.	3.1	72

#	Article	IF	Citations
73	European Prevention of Alzheimerâ€™s Dementia Longitudinal Cohort Study (EPAD LCS): study protocol. BMJ Open, 2018, 8, e021017.	1.9	72
74	Neuropathology of prodromal Lewy body disease. Movement Disorders, 2014, 29, 410-415.	3.9	71
75	Impact of urban environmental exposures on cognitive performance and brain structure of healthy individuals at risk for Alzheimerâ€™s dementia. Environment International, 2020, 138, 105546.	10.0	69
76	Cerebrospinal Fluid Biomarkers and Memory Present Distinct Associations along the Continuum from Healthy Subjects to AD Patients. Journal of Alzheimer's Disease, 2011, 23, 319-326.	2.6	66
77	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research and Therapy, 2018, 10, 100.	6.2	64
78	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimer's Research and Therapy, 2018, 10, 64.	6.2	62
79	Further extension of the H1 haplotype associated with progressive supranuclear palsy. Movement Disorders, 2002, 17, 550-556.	3.9	61
80	Determination of Neuronal Antibodies in Suspected and Definite Creutzfeldt-Jakob Disease. JAMA Neurology, 2014, 71, 74.	9.0	59
81	Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). Neurobiology of Aging, 2017, 53, 1-10.	3.1	59
82	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58
83	Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimerâ€™s dementia: a pooled area under the curve analysis. Alzheimer's Research and Therapy, 2015, 7, 28.	6.2	57
84	Identification of a novel polymorphism in the promoter region of the tau gene highly associated to progressive supranuclear palsy in humans. Neuroscience Letters, 1999, 275, 183-186.	2.1	56
85	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 684-691.	1.9	55
86	Multitracer model for staging cortical amyloid deposition using PET imaging. Neurology, 2020, 95, e1538-e1553.	1.1	55
87	CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Neurobiology of Aging, 2016, 38, 47-55.	3.1	54
88	Association between insomnia and cognitive performance, gray matter volume, and white matter microstructure in cognitively unimpaired adults. Alzheimer's Research and Therapy, 2020, 12, 4.	6.2	53
89	Clinical, Neuropathologic, and Biochemical Profile of the Amyloid Precursor Protein I716F Mutation. Journal of Neuropathology and Experimental Neurology, 2010, 69, 53-59.	1.7	52
90	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid Î² and tau. Alzheimer's and Dementia, 2021, 17, 1575-1582.	0.8	51

#	Article	IF	Citations
91	Informantsâ€™ Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimerâ€™s Disease from NormalÂAging. Journal of Alzheimer's Disease, 2015, 48, S87-S98.	2.6	50
92	Different profiles of Alzheimerâ€™s disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. Journal of Neural Transmission, 2011, 118, 259-262.	2.8	49
93	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomalâ€dominant Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 1251-1260.	0.8	47
94	A Novel Mutation in the PSEN2 Gene (T430M) Associated With Variable Expression in a Family With Early-Onset Alzheimer Disease. Archives of Neurology, 2003, 60, 1149.	4.5	46
95	Secondary prevention of Alzheimerâ€™s dementia: neuroimaging contributions. Alzheimer's Research and Therapy, 2018, 10, 112.	6.2	46
96	Spatial patterns of white matter hyperintensities associated with Alzheimerâ€™s disease risk factors in a cognitively healthy middle-aged cohort. Alzheimer's Research and Therapy, 2019, 11, 12.	6.2	46
97	Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimerâ€™s disease. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641988881.	3.5	46
98	Normative data for the Boston Naming Test and the Pyramids and Palm Trees Test in the elderly Spanish population. Journal of Clinical and Experimental Neuropsychology, 2008, 30, 1-6.	1.3	45
99	CSF microRNA Profiling in Alzheimerâ€™s Disease: a Screening and Validation Study. Molecular Neurobiology, 2017, 54, 6647-6654.	4.0	45
100	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimer's and Dementia, 2021, 17, 1189-1204.	0.8	44
101	White matter microstructure is altered in cognitively normal middle-aged APOE-Îµ4 homozygotes. Alzheimer's Research and Therapy, 2018, 10, 48.	6.2	43
102	Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration. Journal of Neurology, 2008, 255, 488-494.	3.6	40
103	Donepezil Treatment Stabilizes Functional Connectivity During Resting State and Brain Activity During Memory Encoding in Alzheimerâ€™s Disease. Journal of Clinical Psychopharmacology, 2013, 33, 199-205.	1.4	40
104	Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals. Brain Imaging and Behavior, 2020, 14, 2012-2023.	2.1	40
105	CSF Synaptic Biomarkers in the Preclinical Stage of Alzheimer Disease and Their Association With MRI and PET. Neurology, 2021, 97, e2065-e2078.	1.1	40
106	Associations between air pollution and biomarkers of Alzheimerâ€™s disease in cognitively unimpaired individuals. Environment International, 2021, 157, 106864.	10.0	40
107	Using artificial neural networks in clinical neuropsychology: High performance in mild cognitive impairment and Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 195-208.	1.3	39
108	Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. International Journal of Geriatric Psychiatry, 2012, 27, 127-134.	2.7	38

#	Article	IF	Citations
109	AMYPAD Diagnostic and Patient Management Study: Rationale and design. Alzheimer's and Dementia, 2019, 15, 388-399.	0.8	37
110	Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Servicesâ€"part 4 of 6. Alzheimer's Research and Therapy, 2021, 13, 171.	6.2	37
111	Specific Anatomic Associations Between White Matter Integrity and Cognitive Reserve in Normal and Cognitively Impaired Elders. American Journal of Geriatric Psychiatry, 2011, 19, 33-42.	1.2	36
112	Spanish Multicenter Normative Studies (Neuronorma Project): Norms for the Abbreviated Barcelona Test. Archives of Clinical Neuropsychology, 2011, 26, 144-157.	0.5	36
113	Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. Neurodegenerative Diseases, 2016, 16, 69-76.	1.4	36
114	The APOE Îµ4 genotype modulates CSF YKLâ€40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 50-59.	2.4	36
115	Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. Journal of the Neurological Sciences, 2008, 270, 94-98.	0.6	35
116	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Servicesâ€"part 2 of 6. Alzheimer's Research and Therapy, 2021, 13, 169.	6.2	35
117	Exome sequencing in a consanguineous family clinically diagnosed with early-onset Alzheimer's disease identifies a homozygous CTSF mutation. Neurobiology of Aging, 2016, 46, 236.e1-236.e6.	3.1	34
118	Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimerâ€™s Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. Journal of Alzheimer's Disease, 2019, 69, 15-35.	2.6	34
119	APOE Status Modulates the Changes in Network Connectivity Induced by Brain Stimulation in Non-Demented Elders. PLoS ONE, 2012, 7, e51833.	2.5	34
120	The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study. Alzheimer's and Dementia, 2017, 13, 1013-1023.	0.8	33
121	Executive and Language Subjective Cognitive Decline Complaints Discriminate Preclinical Alzheimerâ€™s Disease from Normal Aging. Journal of Alzheimer's Disease, 2017, 61, 689-703.	2.6	33
122	Spanish Multicenter Normative Studies (NEURONORMA Project): Norms for the Visual Object and Space Perception Battery-Abbreviated, and Judgment of Line Orientation. Archives of Clinical Neuropsychology, 2009, 24, 355-370.	0.5	32
123	Impact of transdermal drug delivery on treatment adherence in patients with Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2012, 12, 31-37.	2.8	32
124	Usefulness of Biomarkers in the Diagnosis and Prognosis of Early-Onset Cognitive Impairment. Journal of Alzheimer's Disease, 2014, 40, 919-927.	2.6	32
125	Cost-Effectiveness of the Use of Biomarkers in Cerebrospinal Fluid for Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 777-788.	2.6	32
126	Episodic memory and executive functions in cognitively healthy individuals display distinct neuroanatomical correlates which are differentially modulated by aging. Human Brain Mapping, 2018, 39, 4565-4579.	3.6	32

#	Article	IF	Citations
127	Serum Progranulin Levels in Patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease: Detection of GRN Mutations in a Spanish Cohort. Journal of Alzheimer's Disease, 2012, 31, 581-591.	2.6	31
128	Cost-Utility of Using Alzheimerâ€™s Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. Journal of Alzheimer's Disease, 2017, 60, 1477-1487.	2.6	31
129	Frontotemporal Dementia Caused by the P301L Mutation in the<i> MAPT</i> Gene: Clinicopathological Features of 13 Cases from the Same Geographical Origin in Barcelona, Spain. Dementia and Geriatric Cognitive Disorders, 2017, 44, 213-221.	1.5	31
130	Evolving brain structural changes in PSEN1 mutation carriers. Neurobiology of Aging, 2015, 36, 1261-1270.	3.1	30
131	Interactive effect of age and APOE-Îµ4 allele load on white matter myelin content in cognitively normal middle-aged subjects. NeuroImage: Clinical, 2019, 24, 101983.	2.7	30
132	Enrichment factors for clinical trials in mildâ€toâ€moderate Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 164-174.	3.7	30
133	Personalized risk for clinical progression in cognitively normal subjectsâ€”the ABIDE project. Alzheimer's Research and Therapy, 2019, 11, 33.	6.2	30
134	Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimerâ€™s continuum. Alzheimer's Research and Therapy, 2021, 13, 135.	6.2	30
135	Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimerâ€™s disease. NeuroImage: Clinical, 2019, 22, 101777.	2.7	29
136	Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study. Alzheimer's and Dementia, 2020, 16, 292-304.	0.8	29
137	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2020, 16, 750-758.	0.8	29
138	Incidental findings on brain MRI of cognitively normal first-degree descendants of patients with Alzheimer's disease: a cross-sectional analysis from the ALFA (Alzheimer and Families) project. BMJ Open, 2017, 7, e013215.	1.9	28
139	Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimerâ€™s disease clinical program. Alzheimer's Research and Therapy, 2018, 10, 116.	6.2	28
140	Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. Alzheimer's Research and Therapy, 2019, 11, 74.	6.2	28
141	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's diseaseâ€”Data from three memory clinic studies. Alzheimer's and Dementia, 2019, 15, 185-193.	0.8	28
142	Clinical and Pathological Heterogeneity of Neuronal Intermediate Filament Inclusion Disease. Archives of Neurology, 2008, 65, 272-5.	4.5	27
143	Diagnostic accuracy of behavioral variant frontotemporal dementia consortium criteria (FTDC) in a clinicopathological cohort. Neuropathology and Applied Neurobiology, 2015, 41, 882-892.	3.2	26
144	The SCDâ€Well randomized controlled trial: Effects of a mindfulnessâ€based intervention versus health education on mental health in patients with subjective cognitive decline (SCD). Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 737-745.	3.7	26

#	Article	IF	Citations
145	CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. NeuroImage: Clinical, 2019, 23, 101801.	2.7	26
146	Structural Connectivity Alterations Along the Alzheimerâ€™s Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid-Î² and Tau. Journal of Alzheimer's Disease, 2018, 61, 1575-1587.	2.6	25
147	Cerebrospinal Fluid Biomarkers in Alzheimerâ€™s Disease Families with <i>PSEN1</i> Mutations. Neurodegenerative Diseases, 2011, 8, 202-207.	1.4	24
148	Subclinical Atherosclerosis and Brain Metabolism in Middle-Aged Individuals. Journal of the American College of Cardiology, 2021, 77, 888-898.	2.8	24
149	Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2169-2182.	6.4	24
150	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimerâ€™s Disease: Analytical and Diagnostic Characterization. Journal of Alzheimer's Disease, 2016, 55, 159-170.	2.6	23
151	Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI. Alzheimer's Research and Therapy, 2019, 11, 72.	6.2	23
152	Prevalence of abnormal Alzheimerâ€™s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. Alzheimer's Research and Therapy, 2019, 11, 8.	6.2	23
153	Plasma AÎ²42 as a Biomarker of Prodromal Alzheimerâ€™s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. Journal of Alzheimer's Disease, 2019, 69, 37-48.	2.6	23
154	Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845.	0.8	22
155	Learning non-linear patch embeddings with neural networks for label fusion. Medical Image Analysis, 2018, 44, 143-155.	11.6	21
156	European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. Alzheimer's and Dementia, 2018, 14, 837-842.	0.8	20
157	Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. Psychiatry Research - Neuroimaging, 2011, 192, 140-146.	1.8	19
158	The Rationale Behind the New Alzheimerâ€™s Disease Conceptualization: Lessons Learned During the Last Decades. Journal of Alzheimer's Disease, 2018, 62, 1067-1077.	2.6	19
159	Evolving Brain Functional Abnormalities in PSEN1 Mutation Carriers: A Resting and Visual Encoding fMRI Study. Journal of Alzheimer's Disease, 2013, 36, 165-175.	2.6	19
160	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	2.6	18
161	MRI-Based Screening of Preclinical Alzheimerâ€™s Disease for Prevention Clinical Trials. Journal of Alzheimer's Disease, 2018, 64, 1099-1112.	2.6	18
162	Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimerâ€™s Disease: Structural Brain Biomarkers. Journal of Alzheimer's Disease, 2019, 69, 3-14.	2.6	18

#	Article	IF	Citations
163	APOE-Îµ4 risk variant for Alzheimer's disease modifies the association between cognitive performance and cerebral morphology in healthy middle-aged individuals. NeuroImage: Clinical, 2019, 23, 101818.	2.7	18
164	Effects of a Mindfulness-Based Intervention versus Health Self-Management on Subclinical Anxiety in Older Adults with Subjective Cognitive Decline: The SCD-Well Randomized Superiority Trial. Psychotherapy and Psychosomatics, 2021, 90, 341-350.	8.8	18
165	The amyloid-Î² isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease. Molecular Medicine Reports, 2012, 5, 1111-1115.	2.4	17
166	Quantitative Magnetic Resonance Abnormalities in Creutzfeldt-Jakob Disease and Fatal Insomnia. Journal of Alzheimer's Disease, 2016, 55, 431-443.	2.6	17
167	White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 51, 827-835.	2.6	17
168	Awareness of Cognitive Decline in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. Frontiers in Aging Neuroscience, 2021, 13, 697234.	3.4	17
169	Recomendaciones para la utilizaciÃ³n de biomarcadores de imagen PET en el proceso diagnÃ³stico de las enfermedades neurodegenerativas que cursan con demencia: documento de consenso SEMNIM y SEN. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 303-313.	0.0	16
170	Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. NeuroImage: Clinical, 2018, 19, 190-201.	2.7	16
171	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2183-2199.	6.4	16
172	Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimerâ€™s continuum. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4567-4579.	6.4	16
173	Altered Blood Gene Expression of Tumor-Related Genes (PRKCB, BECN1, and CDKN2A) in Alzheimerâ€™s Disease. Molecular Neurobiology, 2016, 53, 5902-5911.	4.0	15
174	Distinct Cognitive and Brain Morphological Features in Healthy Subjects Unaware of Informant-Reported Cognitive Decline. Journal of Alzheimer's Disease, 2018, 65, 181-191.	2.6	15
175	The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12021.	2.4	15
176	The relation between APOE genotype and cerebral microbleeds in cognitively unimpaired middle- and old-aged individuals. Neurobiology of Aging, 2020, 95, 104-114.	3.1	15
177	Protocols for cognitive enhancement. A user manual for Brain Health Servicesâ€”part 5 of 6. Alzheimer's Research and Therapy, 2021, 13, 172.	6.2	15
178	Cerebral amyloidâ€Î²2 load is associated with neurodegeneration and gliosis: Mediation by pâ€tau and interactions with risk factors early in the Alzheimer'scontinuum. Alzheimer's and Dementia, 2021, 17, 788-800.	0.8	14
179	A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease. Neuroscience Letters, 2011, 496, 40-42.	2.1	13
180	Spanish Multicenter Normative Studies (NEURONORMA Project): Normative Data and Equivalence of Four BNT Short-Form Versions. Archives of Clinical Neuropsychology, 2014, 29, 60-74.	0.5	13

#	Article	IF	Citations
181	Physical activity is associated with better global cognition and frontal function in overweight/obese older adults with metabolic syndrome. European Review of Aging and Physical Activity, 2019, 16, 23.	2.9	13
182	Prevention of cognitive decline in subjective cognitive decline APOE Îµ4 carriers after EGCG and a multimodal intervention (PENSA): Study design. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12155.	3.7	13
183	Amyloid-Î² positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume. Neurobiology of Aging, 2021, 104, 24-31.	3.1	13
184	The protective gene dose effect of the APOEÎµ2 allele on gray matter volume in cognitively unimpaired individuals. Alzheimer's and Dementia, 2022, 18, 1383-1395.	0.8	13
185	Identifying Earlier AlzheimerÂ's Disease: Insights from the Preclinical and Prodromal Phases. Neurodegenerative Diseases, 2012, 10, 158-160.	1.4	12
186	Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings. Alzheimer's Research and Therapy, 2020, 12, 8.	6.2	12
187	Nonlinear interaction between <scp>APOE</scp>Îµ4 allele load and age in the hippocampal surface of cognitively intact individuals. Human Brain Mapping, 2021, 42, 47-64.	3.6	12
188	Brain alterations in the early Alzheimerâ€™s continuum with amyloid-Î², tau, glial and neurodegeneration CSF markers. Brain Communications, 2022, 4, .	3.3	12
189	First demonstrated de novo insertion in the prion protein gene in a young patient with dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 845-846.	1.9	11
190	Wishes and preferences for an online lifestyle program for brain healthâ€”A mixed methods study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 141-149.	3.7	11
191	CSF cutoffs for MCI due to AD depend on APOEÎµ4 carrier status. Neurobiology of Aging, 2020, 89, 55-62.	3.1	11
192	Is there a difference in regional read [18F]flutemetamol amyloid patterns between end-of-life subjects and those with amnestic mild cognitive impairment?. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1299-1308.	6.4	10
193	Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 455-461.	0.8	9
194	Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2021, 13, 46.	6.2	9
195	Management and Quality Control of Large Neuroimaging Datasets: Developments From the BarcelonaÎ²eta Brain Research Center. Frontiers in Neuroscience, 2021, 15, 633438.	2.8	9
196	CSF Proteomic Alzheimerâ€™s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. Proteomes, 2021, 9, 36.	3.5	9
197	Microglial Hyperreactivity Evolved to Immunosuppression in the Hippocampus of a Mouse Model of Accelerated Aging and Alzheimerâ€™s Disease Traits. Frontiers in Aging Neuroscience, 2020, 12, 622360.	3.4	9
198	Age, sex and APOE-Îµ4 modify the balance between soluble and fibrillar Î²-amyloid in non-demented individuals: topographical patterns across two independent cohorts. Molecular Psychiatry, 2022, 27, 2010-2018.	7.9	9

#	Article	IF	Citations
199	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. PLoS ONE, 2022, 17, e0267298.	2.5	9
200	The Open-Access European Prevention of Alzheimerâ€™s Dementia (EPAD) MRI dataset and processing workflow. NeuroImage: Clinical, 2022, 35, 103106.	2.7	9
201	Computerâ€assisted prediction of clinical progression in the earliest stages of AD. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 726-736.	2.4	8
202	Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 69, 49-58.	2.6	8
203	Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 67, 303-313.	2.6	8
204	Effects of COVID-19 Home Confinement on Mental Health in Individuals with Increased Risk of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 79, 1015-1021.	2.6	8
205	Genetic Influences on Hippocampal Subfields. Neurology: Genetics, 2021, 7, e591.	1.9	8
206	Cognitively unimpaired individuals with a low burden of AÎ² pathology have a distinct CSF biomarker profile. Alzheimer's Research and Therapy, 2021, 13, 134.	6.2	8
207	APOE-Îµ4 Shapes the Cerebral Organization in Cognitively Intact Individuals as Reflected by Structural Gray Matter Networks. Cerebral Cortex, 2020, 30, 4110-4120.	2.9	7
208	Brain correlates of urban environmental exposures in cognitively unimpaired individuals at increased risk for Alzheimer's disease: A study on Barcelona's population. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12205.	2.4	7
209	Genetic Predisposition to Alzheimerâ€™s Disease Is Associated with Enlargement of Perivascular Spaces in Centrum Semiovale Region. Genes, 2021, 12, 825.	2.4	7
210	Sex-Specific Metabolic Pathways Were Associated with Alzheimerâ€™s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	3.2	7
211	Modeling practice effects in healthy middleâ€aged participants of the Alzheimer and Families parent cohort. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 149-158.	2.4	6
212	Associations Between the Subjective Cognitive Decline-Questionnaireâ€™s Scores, Gray Matter Volume, and Amyloid-Î² Levels. Journal of Alzheimer's Disease, 2019, 72, 1287-1302.	2.6	6
213	Quantitative informantâ€and selfâ€reports of subjective cognitive decline predict amyloid beta PET outcomes in cognitively unimpaired individuals independently of age and APOE Îµ4. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12127.	2.4	6
214	Accelerated longâ€term forgetting in individuals with subjective cognitive decline and amyloidâ€Î² positivity. International Journal of Geriatric Psychiatry, 2021, 36, 1037-1049.	2.7	6
215	Description of a European memory clinic cohort undergoing amyloidâ€PET: The AMYPAD Diagnostic and Patient Management Study. Alzheimer's and Dementia, 2023, 19, 844-856.	0.8	6
216	Preservation of cell-survival mechanisms by the presenilin-1 K239N mutation may cause its milder clinical phenotype. Neurobiology of Aging, 2016, 46, 169-179.	3.1	5

#	Article	IF	Citations
217	Effect of BDNF Val66Met on hippocampal subfields volumes and compensatory interaction with APOE-Îµ4 in middle-age cognitively unimpaired individuals from the ALFA study. Brain Structure and Function, 2020, 225, 2331-2345.	2.3	5
218	A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimerâ€™s Disease: Towards a More Continuous Approach. Journal of Alzheimer's Disease, 2022, 86, 511-524.	2.6	5
219	Genotypic effects ofAPOE-Îµ4 on resting-state connectivity in cognitively intact individuals support functional brain compensation. Cerebral Cortex, 2023, 33, 2748-2760.	2.9	5
220	[P4â€“157]: CSF BIOMARKERS AND EFFECT OF APOLIPOPROTEIN E GENOTYPE, AGE AND SEX ON CUTâ€OFF DERIVATION IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1319.	0.8	4
221	Tauopathy with Hippocampal 4â€Repeat Tau Immunoreactive Spherical Inclusions in a Patient with PSP. Brain Pathology, 2018, 28, 284-286.	4.1	4
222	Sex Differences of Longitudinal Brain Changes in Cognitively Unimpaired Adults. Journal of Alzheimer's Disease, 2020, 76, 1413-1422.	2.6	4
223	Harmonisation and Between-Country Differences of the Lifetime of Experiences Questionnaire in Older Adults. Frontiers in Aging Neuroscience, 2021, 13, 740005.	3.4	4
224	Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: consensus proposal from the SEMNIM and SEN. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2015, 34, 303-313.	0.2	3
225	Association of years to parent's sporadic onset and risk factors with neural integrity and Alzheimer biomarkers. Neurology, 2020, 95, e2065-e2074.	1.1	3
226	Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarker Levels. Journal of Alzheimer's Disease, 2021, 84, 119-128.	2.6	3
227	Clinical Observational Research on Alzheimer's Disease: What Clinical Trial Registries Can Tell. Journal of Alzheimer's Disease, 2013, 34, 183-190.	2.6	2
228	P2-302: CSF Beta-Amyloid- and APOE Æ4-Related Decline in Episodic Memory Over 12 Months Measured using the Cantab in Individuals with Amnestic MCI: Results from the European ADNI Study. , 2016, 12, P751-P751.		2
229	[P1â€“058]: RESPONDER ANALYSIS OF THE COGNITIVE EFFECT OF COMBINATION THERAPY WITH DONEPEZIL AND INTEPIRDINE (RVTâ€101) VERSUS DONEPEZIL MONOTHERAPY: RESULTS FROM A 48â€WEEK MULTINATIONAL PLACEBOâ€CONTROLLED STUDY IN MILD TO MODERATE ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P259.	0.8	2
230	Harmonization of amyloid PET scans minimizes the impact of reconstruction parameters on centiloid values. Alzheimer's and Dementia, 2020, 16, e045294.	0.8	2
231	Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium. Alzheimer's and Dementia, 2022, 18, 1957-1968.	0.8	2
232	Measuring decline in prodromal AD: a pike to hike. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 358-358.	1.9	1
233	P3â€315: Differential Effects of Apoe and CSF Amyloid on Memory Impairment in Individuals with Amnestic MCI Using the Cantab Cognitive Battery: Results from the Europeanâ€Adni Study. Alzheimer's and Dementia, 2016, 12, P964.	0.8	1
234	[P2â€“212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER's DISEASE (EMIFâ€AD): THE BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2017, 13, P691.	0.8	1

#	Article	IF	Citations
235	Emerging betaâ€amyloid pathology is associated with tau, synaptic, neurodegeneration and gray matter volume differences. Alzheimer's and Dementia, 2020, 16, e044466.	0.8	1
236	Betweenâ€country harmonization and differences of the Lifetime of Experiences Questionnaire (LEQ) for lifespan complex mental activity assessment. Alzheimer's and Dementia, 2020, 16, e045240.	0.8	1
237	Impact of APOE â€Îµ4 on cerebral amyloid deposition in participants with abnormal soluble amyloid levels. Alzheimer's and Dementia, 2020, 16, e045828.	0.8	1
238	Selfâ€reflection is associated with markers of Alzheimerâ€™s disease in cognitively unimpaired older adults. Alzheimer's and Dementia, 2021, 17, .	0.8	1
239	Reply. Annals of Neurology, 2014, 75, 460-461.	5.3	0
240	P2â€335: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples. Alzheimer's and Dementia, 2016, 12, P770.	0.8	0
241	[P2â€“355]: CSF STREM2, BUT NOT YKLâ€40, IS ASSOCIATED WITH LONGITUDINAL MORPHOLOGICAL BRAIN CHANGES IN PRECLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P758.	0.8	0
242	[P3â€“566]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P1195.	0.8	0
243	[P4â€“214]: TOWARD A FUNCTIONAL NEUROMARKER FOR PRECLINICAL AD: EIGENVECTOR CENTRALITY REVEALS PRECLINICAL DIFFERENCES OF FUNCTIONAL INFORMATION FLOW IN THE HIPPOCAMPUS, PRECUNEUS, CEREBELLUM AND INFERIOR PARIETAL LOBULE. Alzheimer's and Dementia, 2017, 13, P1348.	0.8	0
244	[P4â€“377]: EXPECTATIONS RELATED TO THE IMPLICATIONS OF LEARNING ALZHEIMER's DISEASE RISK AMONG COGNITIVELY HEALTHY RESEARCH PARTICIPANTS. Alzheimer's and Dementia, 2017, 13, P1437.	0.8	0
245	[TDâ€Pâ€020]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P166.	0.8	0
246	[P1â€“289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF AÎ² OR AMYLOIDâ€PET) IN THE EMIFâ€AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2017, 13, P361.	0.8	0
247	[O1â€“11â€“03]: CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P218.	0.8	0
248	P2â€262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM. Alzheimer's and Dementia, 2018, 14, P777.	0.8	0
249	P2â€458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIFâ€AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P895.	0.8	0
250	ICâ€02â€05: GENDER DIFFERENCES IN THE ASSOCIATION BETWEEN LONGITUDINAL BRAIN CHANGES AND BASELINE LEVELS OF CSF ALZHEIMER'S DISEASE AND GLIAL BIOMARKERS IN HEALTHY ELDERS. Alzheimer's and Dementia, 2019, 15, P4.	0.8	0
251	Operationalization of the ATN classification scheme in preclinical AD: Findings from EPAD V500.0 data release. Alzheimer's and Dementia, 2020, 16, e037912.	0.8	0
252	Use of the Medtep digital health platform in the framework of a multimodal intervention in patients with subjective cognitive decline (PENSA Study). Alzheimer's and Dementia, 2020, 16, e040447.	0.8	0

#	Article	IF	Citations
253	Examining centiloid quantification against visual assessment using [18F]flutemetamol PET. Alzheimer's and Dementia, 2020, 16, e042653.	0.8	0
254	Polygenicâ€wide analysis to assess the impact of genetic risk profiles on brain morphometry in the ALFA study. Alzheimer's and Dementia, 2020, 16, e042952.	0.8	0
255	Impact of the APOE gene on amyloid deposition in participants with abnormal soluble amyloid levels. Alzheimer's and Dementia, 2020, 16, e042955.	0.8	0
256	Subjective cognitive decline correlates with medial temporal lobe and hippocampal subfield volumetry in cognitively unimpaired participants. Alzheimer's and Dementia, 2020, 16, e043520.	0.8	0
257	Amyloidâ€Î², tau, synaptic dysfunction, neurodegeneration, glial and vascular biomarkers in the preclinical stage of the Alzheimerâ€™s continuum. Alzheimer's and Dementia, 2020, 16, e044444.	0.8	0
258	Genetically predicted telomere length and Alzheimerâ€™s disease endophenotypes: A Mendelian randomization study. Alzheimer's and Dementia, 2020, 16, e044720.	0.8	0
259	The effect of physical activity on CSF biomarkers of Alzheimerâ€™s disease differs between men and women. Alzheimer's and Dementia, 2020, 16, e044722.	0.8	0
260	Multiple biological pathways associate with cerebral amyloid load in the early Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, e044733.	0.8	0
261	Higher frontoâ€parietal metabolism parallels a greater impact of amyloid and anxiety on medial temporal areas in women versus men. Alzheimer's and Dementia, 2020, 16, e044780.	0.8	0
262	Multiple pathophysiological biomarkers are associated with gray matter volume and cerebral glucose metabolism in the early preclinical Alzheimer's continuum. Alzheimer's and Dementia, 2020, 16, e044808.	0.8	0
263	PENSA study: Study design, recruitment profiles and participant inclusion in multimodal intervention studies. Alzheimer's and Dementia, 2020, 16, e045074.	0.8	0
264	APOE â€•Îµ4 shapes temporoâ€parietal network properties in middleâ€aged, cognitively unimpaired individuals: A graph theory analysis. Alzheimer's and Dementia, 2020, 16, e045092.	0.8	0
265	Weight loss predicts Alzheimerâ€™s disease biomarker positivity in cognitively unimpaired middleâ€aged adults. Alzheimer's and Dementia, 2020, 16, e045137.	0.8	0
266	Proximity to parental age at onset exacerbates amyloid burden while mental conditions exacerbate neural loss during midlife. Alzheimer's and Dementia, 2020, 16, e045171.	0.8	0
267	Incidence of subjective cognitive decline is associated with amyloidâ€Î² pathology, whereas stability relates to neurodegeneration. Alzheimer's and Dementia, 2020, 16, e045293.	0.8	0
268	Amyloidâ€positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to hippocampal volume. Alzheimer's and Dementia, 2020, 16, e045715.	0.8	0
269	The Barcelonabeta dementia prevention research clinic: Study design, recruitment profiles and inclusion in prevention studies â€” An update. Alzheimer's and Dementia, 2020, 16, e045800.	0.8	0
270	ALFA+: A cohort study to understand and model the preclinical stage of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e045935.	0.8	0

#	Article	IF	Citations
271	NeAT: a Nonlinear Analysis Toolbox for Neuroimaging. Neuroinformatics, 2020, 18, 517-530.	2.8	0
272	Soundtrack of life: An fMRI study. Behavioural Brain Research, 2022, 418, 113634.	2.2	0
273	Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies. Methods in Molecular Biology, 2018, 1750, 165-184.	0.9	0
274	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18 F]flutemetamol PET images. Alzheimer's and Dementia, 2020, 16, .	0.8	0
275	A coâ€creation approach to design the implementation of a multimodal intervention in patients with subjective cognitive decline (PENSA study). Alzheimer's and Dementia, 2020, 16, e042998.	0.8	0
276	Network analysis for studying the dynamics of affective symptoms and treatment adherence in APOEâ€É›4 carriers with subjective cognitive decline following a multimodal intervention: Preliminary findings from the PENSA Study. Alzheimer's and Dementia, 2021, 17, .	0.8	0